Interactions between the complement and endothelin systems in normal pregnancy and following placental ischemia

Jean F Regal, Jenna M. Lund, Cameron R. Wing, Kate M. Root, Luke McCutcheon, Lynne T Bemis, Jeffrey S. Gilbert, Sherry D. Fleming

Research output: Contribution to journalArticle

Abstract

Preeclampsia is characterized by new onset hypertension and fetal growth restriction and is associated with aberrant activation of the innate immune complement system and stressed or ischemic placenta. Previous studies have suggested a role for both endothelin and complement system activation products in new onset hypertension in pregnancy, but inter-relationships of the pathways are unclear. We hypothesized that complement activation following placental ischemia stimulates the endothelin pathway to cause hypertension and impair fetal growth. The Reduced Uterine Perfusion Pressure (RUPP) model results in hypertension and fetal growth restriction in a pregnant rat due to placental ischemia caused by mechanical obstruction of blood flow to uterus and placenta. The effect of inhibitor of complement activation soluble Complement Receptor 1 (sCR1) and endothelin A receptor (ETA) antagonist atrasentan on hypertension, fetal weight, complement activation (systemic circulating C3a and local C3 placental deposition) and endothelin [circulating endothelin and message for preproendothelin (PPE), ETA and endothelin B receptor (ETB) in placenta] in the RUPP rat model were determined. Following placental ischemia, sCR1 attenuated hypertension but increased message for PPE and ETA in placenta, suggesting complement activation causes hypertension via an endothelin independent pathway. With ETA antagonism the placental ischemia-induced increase in circulating C3a was unaffected despite inhibition of hypertension, indicating systemic C3a alone is not sufficient. In normal pregnancy, inhibiting complement activation increased plasma endothelin but not placental PPE message. Atrasentan treatment increased fetal weight, circulating endothelin and placental ETA message, and unexpectedly increased local complement activation in placenta (C3 deposition) but not C3a in circulation, suggesting endothelin controls local placental complement activation in normal pregnancy. Atrasentan also significantly decreased message for endogenous complement regulators Crry and CD55 in placenta and kidney in normal pregnancy. Results of our study indicate that complement/endothelin interactions differ in pregnancies complicated with placental ischemia vs normal pregnancy, as well as locally vs systemically. These data clearly illustrate the complex interplay between complement and endothelin indicating that perturbations of either pathway may affect pregnancy outcomes.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalMolecular Immunology
Volume114
DOIs
StatePublished - Oct 1 2019

Fingerprint

Endothelins
Complement Activation
Ischemia
Pregnancy
Placenta
Hypertension
Endothelin A Receptors
Endothelin-1
Fetal Development
Complement C1
Complement Receptors
Fetal Weight
Perfusion
Endothelin B Receptors
Pressure
Pregnancy Outcome
Pre-Eclampsia
Uterus
Immune System
Kidney

Keywords

  • Complement
  • Endothelin
  • Placental ischemia
  • Pregnancy

Cite this

Interactions between the complement and endothelin systems in normal pregnancy and following placental ischemia. / Regal, Jean F; Lund, Jenna M.; Wing, Cameron R.; Root, Kate M.; McCutcheon, Luke; Bemis, Lynne T; Gilbert, Jeffrey S.; Fleming, Sherry D.

In: Molecular Immunology, Vol. 114, 01.10.2019, p. 10-18.

Research output: Contribution to journalArticle

Regal, Jean F ; Lund, Jenna M. ; Wing, Cameron R. ; Root, Kate M. ; McCutcheon, Luke ; Bemis, Lynne T ; Gilbert, Jeffrey S. ; Fleming, Sherry D. / Interactions between the complement and endothelin systems in normal pregnancy and following placental ischemia. In: Molecular Immunology. 2019 ; Vol. 114. pp. 10-18.
@article{9e0f7d5d33dc43419dfadcc9df26ba72,
title = "Interactions between the complement and endothelin systems in normal pregnancy and following placental ischemia",
abstract = "Preeclampsia is characterized by new onset hypertension and fetal growth restriction and is associated with aberrant activation of the innate immune complement system and stressed or ischemic placenta. Previous studies have suggested a role for both endothelin and complement system activation products in new onset hypertension in pregnancy, but inter-relationships of the pathways are unclear. We hypothesized that complement activation following placental ischemia stimulates the endothelin pathway to cause hypertension and impair fetal growth. The Reduced Uterine Perfusion Pressure (RUPP) model results in hypertension and fetal growth restriction in a pregnant rat due to placental ischemia caused by mechanical obstruction of blood flow to uterus and placenta. The effect of inhibitor of complement activation soluble Complement Receptor 1 (sCR1) and endothelin A receptor (ETA) antagonist atrasentan on hypertension, fetal weight, complement activation (systemic circulating C3a and local C3 placental deposition) and endothelin [circulating endothelin and message for preproendothelin (PPE), ETA and endothelin B receptor (ETB) in placenta] in the RUPP rat model were determined. Following placental ischemia, sCR1 attenuated hypertension but increased message for PPE and ETA in placenta, suggesting complement activation causes hypertension via an endothelin independent pathway. With ETA antagonism the placental ischemia-induced increase in circulating C3a was unaffected despite inhibition of hypertension, indicating systemic C3a alone is not sufficient. In normal pregnancy, inhibiting complement activation increased plasma endothelin but not placental PPE message. Atrasentan treatment increased fetal weight, circulating endothelin and placental ETA message, and unexpectedly increased local complement activation in placenta (C3 deposition) but not C3a in circulation, suggesting endothelin controls local placental complement activation in normal pregnancy. Atrasentan also significantly decreased message for endogenous complement regulators Crry and CD55 in placenta and kidney in normal pregnancy. Results of our study indicate that complement/endothelin interactions differ in pregnancies complicated with placental ischemia vs normal pregnancy, as well as locally vs systemically. These data clearly illustrate the complex interplay between complement and endothelin indicating that perturbations of either pathway may affect pregnancy outcomes.",
keywords = "Complement, Endothelin, Placental ischemia, Pregnancy",
author = "Regal, {Jean F} and Lund, {Jenna M.} and Wing, {Cameron R.} and Root, {Kate M.} and Luke McCutcheon and Bemis, {Lynne T} and Gilbert, {Jeffrey S.} and Fleming, {Sherry D.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.molimm.2019.06.015",
language = "English (US)",
volume = "114",
pages = "10--18",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Interactions between the complement and endothelin systems in normal pregnancy and following placental ischemia

AU - Regal, Jean F

AU - Lund, Jenna M.

AU - Wing, Cameron R.

AU - Root, Kate M.

AU - McCutcheon, Luke

AU - Bemis, Lynne T

AU - Gilbert, Jeffrey S.

AU - Fleming, Sherry D.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Preeclampsia is characterized by new onset hypertension and fetal growth restriction and is associated with aberrant activation of the innate immune complement system and stressed or ischemic placenta. Previous studies have suggested a role for both endothelin and complement system activation products in new onset hypertension in pregnancy, but inter-relationships of the pathways are unclear. We hypothesized that complement activation following placental ischemia stimulates the endothelin pathway to cause hypertension and impair fetal growth. The Reduced Uterine Perfusion Pressure (RUPP) model results in hypertension and fetal growth restriction in a pregnant rat due to placental ischemia caused by mechanical obstruction of blood flow to uterus and placenta. The effect of inhibitor of complement activation soluble Complement Receptor 1 (sCR1) and endothelin A receptor (ETA) antagonist atrasentan on hypertension, fetal weight, complement activation (systemic circulating C3a and local C3 placental deposition) and endothelin [circulating endothelin and message for preproendothelin (PPE), ETA and endothelin B receptor (ETB) in placenta] in the RUPP rat model were determined. Following placental ischemia, sCR1 attenuated hypertension but increased message for PPE and ETA in placenta, suggesting complement activation causes hypertension via an endothelin independent pathway. With ETA antagonism the placental ischemia-induced increase in circulating C3a was unaffected despite inhibition of hypertension, indicating systemic C3a alone is not sufficient. In normal pregnancy, inhibiting complement activation increased plasma endothelin but not placental PPE message. Atrasentan treatment increased fetal weight, circulating endothelin and placental ETA message, and unexpectedly increased local complement activation in placenta (C3 deposition) but not C3a in circulation, suggesting endothelin controls local placental complement activation in normal pregnancy. Atrasentan also significantly decreased message for endogenous complement regulators Crry and CD55 in placenta and kidney in normal pregnancy. Results of our study indicate that complement/endothelin interactions differ in pregnancies complicated with placental ischemia vs normal pregnancy, as well as locally vs systemically. These data clearly illustrate the complex interplay between complement and endothelin indicating that perturbations of either pathway may affect pregnancy outcomes.

AB - Preeclampsia is characterized by new onset hypertension and fetal growth restriction and is associated with aberrant activation of the innate immune complement system and stressed or ischemic placenta. Previous studies have suggested a role for both endothelin and complement system activation products in new onset hypertension in pregnancy, but inter-relationships of the pathways are unclear. We hypothesized that complement activation following placental ischemia stimulates the endothelin pathway to cause hypertension and impair fetal growth. The Reduced Uterine Perfusion Pressure (RUPP) model results in hypertension and fetal growth restriction in a pregnant rat due to placental ischemia caused by mechanical obstruction of blood flow to uterus and placenta. The effect of inhibitor of complement activation soluble Complement Receptor 1 (sCR1) and endothelin A receptor (ETA) antagonist atrasentan on hypertension, fetal weight, complement activation (systemic circulating C3a and local C3 placental deposition) and endothelin [circulating endothelin and message for preproendothelin (PPE), ETA and endothelin B receptor (ETB) in placenta] in the RUPP rat model were determined. Following placental ischemia, sCR1 attenuated hypertension but increased message for PPE and ETA in placenta, suggesting complement activation causes hypertension via an endothelin independent pathway. With ETA antagonism the placental ischemia-induced increase in circulating C3a was unaffected despite inhibition of hypertension, indicating systemic C3a alone is not sufficient. In normal pregnancy, inhibiting complement activation increased plasma endothelin but not placental PPE message. Atrasentan treatment increased fetal weight, circulating endothelin and placental ETA message, and unexpectedly increased local complement activation in placenta (C3 deposition) but not C3a in circulation, suggesting endothelin controls local placental complement activation in normal pregnancy. Atrasentan also significantly decreased message for endogenous complement regulators Crry and CD55 in placenta and kidney in normal pregnancy. Results of our study indicate that complement/endothelin interactions differ in pregnancies complicated with placental ischemia vs normal pregnancy, as well as locally vs systemically. These data clearly illustrate the complex interplay between complement and endothelin indicating that perturbations of either pathway may affect pregnancy outcomes.

KW - Complement

KW - Endothelin

KW - Placental ischemia

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85069615626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069615626&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2019.06.015

DO - 10.1016/j.molimm.2019.06.015

M3 - Article

C2 - 31326653

AN - SCOPUS:85069615626

VL - 114

SP - 10

EP - 18

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

ER -